A Randomised, Double-Blind, Parallel-Group, Placebo Controlled Phase II Study to Assess the Clinical Benefit of 3 Doses of PAX-1 as Adjunctive Treatment for Persistent Cancer Pain
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs PAX 1 (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 28 Oct 2016 Planned End Date changed from 31 Jul 2016 to 31 Jul 2018.
- 28 Oct 2016 Planned initiation date changed from 30 Oct 2015 to 30 Oct 2016.
- 01 Jul 2016 New trial record